CN115501305B - Traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness and application thereof - Google Patents
Traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness and application thereof Download PDFInfo
- Publication number
- CN115501305B CN115501305B CN202211310613.6A CN202211310613A CN115501305B CN 115501305 B CN115501305 B CN 115501305B CN 202211310613 A CN202211310613 A CN 202211310613A CN 115501305 B CN115501305 B CN 115501305B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- depression
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 107
- 210000004185 liver Anatomy 0.000 title claims abstract description 69
- 210000000952 spleen Anatomy 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000007812 deficiency Effects 0.000 title claims abstract description 37
- 241000202726 Bupleurum Species 0.000 claims abstract description 26
- 241001522129 Pinellia Species 0.000 claims abstract description 26
- 241000132012 Atractylodes Species 0.000 claims abstract description 23
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 23
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 23
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 23
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 23
- 241000237502 Ostreidae Species 0.000 claims abstract description 23
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 23
- 235000020636 oyster Nutrition 0.000 claims abstract description 23
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims abstract description 22
- 235000017491 Bambusa tulda Nutrition 0.000 claims abstract description 22
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims abstract description 22
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 22
- 244000197580 Poria cocos Species 0.000 claims abstract description 22
- 239000011425 bamboo Substances 0.000 claims abstract description 22
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 22
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 21
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 21
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 21
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 19
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 19
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 19
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 19
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 16
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 16
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims abstract description 14
- 240000005001 Paeonia suffruticosa Species 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 5
- 241000213006 Angelica dahurica Species 0.000 claims abstract 5
- 244000082204 Phyllostachys viridis Species 0.000 claims abstract 5
- 238000000034 method Methods 0.000 claims description 114
- 210000000232 gallbladder Anatomy 0.000 claims description 30
- 210000002784 stomach Anatomy 0.000 claims description 30
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 26
- 208000026435 phlegm Diseases 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 206010003591 Ataxia Diseases 0.000 claims description 8
- 206010010947 Coordination abnormal Diseases 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 208000016290 incoordination Diseases 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 7
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 6
- 241001106477 Paeoniaceae Species 0.000 claims description 6
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- -1 decoction Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 235000008504 concentrate Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000006679 Mentha X verticillata Nutrition 0.000 claims 1
- 235000002899 Mentha suaveolens Nutrition 0.000 claims 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 46
- 238000011282 treatment Methods 0.000 abstract description 43
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 229940126673 western medicines Drugs 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 description 46
- 229940079593 drug Drugs 0.000 description 21
- 241001330002 Bambuseae Species 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 15
- 208000011580 syndromic disease Diseases 0.000 description 15
- 241000382455 Angelica sinensis Species 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000008451 emotion Effects 0.000 description 10
- 208000019901 Anxiety disease Diseases 0.000 description 9
- 230000036506 anxiety Effects 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000001835 viscera Anatomy 0.000 description 8
- 208000020401 Depressive disease Diseases 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 238000012346 open field test Methods 0.000 description 7
- 206010010144 Completed suicide Diseases 0.000 description 6
- 206010038743 Restlessness Diseases 0.000 description 6
- 230000001174 ascending effect Effects 0.000 description 6
- 239000009752 danzhi xiaoyao Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 206010061428 decreased appetite Diseases 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000014347 soups Nutrition 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 208000001431 Psychomotor Agitation Diseases 0.000 description 5
- 208000022531 anorexia Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 244000061520 Angelica archangelica Species 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 description 4
- 206010022998 Irritability Diseases 0.000 description 4
- 208000032023 Signs and Symptoms Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000016261 weight loss Diseases 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 3
- 208000031091 Amnestic disease Diseases 0.000 description 3
- 206010011469 Crying Diseases 0.000 description 3
- 206010012239 Delusion Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000006986 amnesia Effects 0.000 description 3
- 231100000868 delusion Toxicity 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- 208000004356 Hysteria Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 208000012839 conversion disease Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002898 effect on depression Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000009428 kamisyoyo san Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 201000000484 premenstrual tension Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical group O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100036441 Amyloid-beta A4 precursor protein-binding family A member 2 Human genes 0.000 description 1
- 101710093616 Amyloid-beta A4 precursor protein-binding family A member 2 Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010061549 Sensation of foreign body Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000012048 forced swim test Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960005183 paroxetine hydrochloride Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008539 xiaoyao Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6-20 parts of purified pinellia tuber, 6-20 parts of bupleurum, 6-20 parts of white peony root, 6-20 parts of bamboo shavings, 6-30 parts of immature bitter orange, 6-30 parts of stir-fried bighead atractylodes rhizome, 6-20 parts of Chinese angelica, 6-20 parts of tree peony bark, 6-20 parts of cape jasmine, 6-20 parts of dried orange peel, 6-20 parts of poria cocos, 9-30 parts of dragon bone, 9-30 parts of oyster, 3-15 parts of peppermint and 6-20 parts of honey-fried licorice root. The traditional Chinese medicine composition provided by the invention is safe, quick in effect, good in treatment effect, free of toxic and side effects, easy to accept by patients and capable of avoiding toxic and side effects caused by using western medicines in large doses.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness, and particularly relates to a traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness, and a preparation method and application thereof.
Background
Depression, which is a mood disorder, also known as depressive disorder or depressive episode, is a disease caused by various causes and mainly manifested by depression of mood, and patients often have the ideas of loss of interest, self-crime, difficulty in noticing, loss of appetite and suicide, and are accompanied by other abnormalities in cognition, behavior and social functioning. Depression belongs to global high-incidence mental diseases, has the characteristics of high prevalence rate, high disability rate, high suicide rate and high recurrence rate, and brings serious social and economic burden. With the continuous aggravation of social competition, the life pressure is gradually increased, the prevalence rate of depression is in a year-by-year rising trend, and the prevalence population tends to be younger. World health organization (World Health Organization, WHO) reports in 2017 show that up to 3.22 million people worldwide are currently suffering from depression, with prevalence of about 4.4% and annual suicide deaths approaching 80 ten thousand, will be the second next second most serious disease to cardiovascular disease.
At present, the treatment of depression is mainly carried out by taking antidepressant drugs orally, and the depression symptoms can be relieved, but the problems of high recurrence rate, long administration period, poor patient compliance, large side effect, possibility of increasing suicide tendency and the like exist. How to effectively improve the treatment effect of depression has become a major problem to be solved in the field. The traditional Chinese medicine is based on the whole concept and dialectical treatment, can effectively improve clinical symptoms of depression patients, improves the life quality of the depression patients, and has the unique advantages of stable curative effect, low recurrence rate, less side effect, good patient compliance and the like in the aspect of prevention and treatment of depression. The traditional Chinese patent medicines commonly used for treating depression in the market at present are as follows: depression-relieving and liver-soothing pill, bupleurum liver-soothing pill, liver-soothing and depression-relieving capsule, xiaoyao pill, jie Yuwan, yueju pill and the like. The product has two defects: 1. insufficient efficacy, or excessive attack and damage to healthy qi, or single action to treat symptoms but not root cause, or alleviation of overlong taking period; 2. the dosage forms are not enough, and most of the dosage forms are pills, so that the pill is slow and the curative effect of the medicine is hindered.
Therefore, it is necessary to develop a Chinese medicinal composition which has good efficacy and quick response and is used for treating depression.
Disclosure of Invention
In view of the above technical problems, the present invention provides the following technical solutions:
the first aspect of the invention provides a traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness, which is prepared from the following raw materials in parts by weight: 6-20 parts of purified pinellia tuber, 6-20 parts of bupleurum, 6-20 parts of white peony root, 6-20 parts of bamboo shavings, 6-30 parts of immature bitter orange, 6-30 parts of stir-fried bighead atractylodes rhizome, 6-20 parts of Chinese angelica, 6-20 parts of tree peony bark, 6-20 parts of cape jasmine, 6-20 parts of dried orange peel, 6-20 parts of poria cocos, 9-30 parts of dragon bone, 9-30 parts of oyster, 3-15 parts of peppermint and 6-20 parts of honey-fried licorice root.
Preferably, the feed additive is prepared from the following raw materials in parts by weight: 15 parts of purified pinellia tuber, 10 parts of bupleurum, 15 parts of white peony root, 15 parts of bamboo shavings, 20 parts of immature bitter orange, 20 parts of stir-fried bighead atractylodes rhizome, 10 parts of Chinese angelica, 15 parts of tree peony bark, 10 parts of gardenia, 20 parts of dried orange peel, 15 parts of poria cocos, 30 parts of dragon bone, 30 parts of oyster, 6 parts of peppermint and 10 parts of honey-fried licorice root.
The second aspect of the invention provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
weighing purified pinellia tuber, bupleurum, white paeony root, bamboo shavings, immature bitter orange, stir-fried bighead atractylodes rhizome, chinese angelica, moutan bark, gardenia, dried orange peel, tuckahoe, dragon bone, oyster, peppermint and honey-fried licorice root according to parts by weight for standby;
decocting the weighed medicinal materials in water, and collecting decoction to obtain the traditional Chinese medicine composition.
Preferably, the specific operation process of water adding decoction comprises the following steps: adding water which is 6-8 times of the total amount of the medicinal materials into the mixed medicinal materials, decocting for 2-3 times, each time for 1.0-1.5 h, mixing the decoctions, and filtering.
The third aspect of the invention provides an application of the traditional Chinese medicine composition in preparing a medicament for treating depression.
Preferably, the depression is caused by liver depression, spleen deficiency, incoordination between gallbladder and stomach, and phlegm dampness stagnation.
The fourth aspect of the invention provides a medicament for treating depression, which comprises the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials or carriers.
Preferably, the medicament is in the form of granules, tablets, decoction, capsules or syrup.
The fifth aspect of the invention provides a traditional Chinese medicine granule for treating depression caused by liver depression and spleen deficiency and excessive dampness, which comprises the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
The sixth aspect of the invention provides a preparation method of the traditional Chinese medicine granule, comprising the following steps:
weighing purified pinellia tuber, bupleurum, white paeony root, bamboo shavings, immature bitter orange, stir-fried bighead atractylodes rhizome, chinese angelica, moutan bark, gardenia, dried orange peel, tuckahoe, dragon bone, oyster, peppermint and honey-fried licorice root according to parts by weight for standby;
mixing the weighed medicinal materials, decocting in water, collecting decoction, concentrating at 50 ℃ and minus 0.06 to minus 0.08mpa, adding sugar powder and soluble starch into the obtained concentrate, granulating, drying and finishing.
The depression belongs to the category of depression syndrome in traditional Chinese medicine, and clinical symptoms of depression can be classified into deficiency of the kidney and liver depression syndrome, deficiency of the liver and spleen syndrome, deficiency of both the heart and spleen syndrome, incoordination between the heart and kidney, damp-heat of liver and gallbladder and deficiency of heart and gallbladder according to the diagnosis standard and treatment scheme of depression traditional Chinese medicine. The first depression in the international Chinese medical clinical practice guideline-first depression has the symptoms of liver depression and qi stagnation, liver depression and spleen deficiency, heart and spleen deficiency, kidney deficiency and liver depression, and liver and gall damp-heat.
The traditional Chinese medicine composition provided by the invention treats depression by using liver, gall and spleen and stomach integrated theory. Liver governs smoothing flow of qi, gallbladder governs resolution, and regulates qi movement of the whole body; spleen and stomach are the middle energizer and are the junction for qi movement. Liver and gallbladder and spleen and stomach play an important role in ascending, descending, exiting and entering of qi movement, and qi movement in the body depends on liver and gallbladder qi dredging, spleen and stomach ascending, clearing, descending and turbid. Lidong chong is very important in looking at the ascending action of gallbladder qi, and it is considered that the gallbladder and stomach are interdependent in promoting hair growth, and they are used for each other. If spleen and stomach are weak, gallbladder qi will not rise; however, the ascending of stomach-qi is affected by the non-ascending of gallbladder qi. He states in the theory of spleen and stomach theory, theory of transformation of deficiency and excess of spleen and stomach: for gallbladder, qi generated in the spring and the transformation of qi in the spring are all the more pronounced, so the gallbladder qi is generated in the spring and the rest of the viscera is derived from the gallbladder qi. "in" Lanchuang Micang-spleen and kidney deficiency theory ", it is proposed that: the "the diet of a person enters the stomach, and nutrient qi rises, i.e., there is less Yang Jia gallbladder qi. ". Liver failing to drain for a long time, liver diseases transmitting spleen, spleen failing to transport, brewing and producing turbid phlegm, phlegm-fire being mutually combined, ascending and descending with qi, upper cross-flow and disturbance of heart, loss of spirit and machine, light symptoms of anxiety, dysphoria, out-of-control emotion and the like, heavy symptoms of mania, restlessness, noisy and cursory and other abnormal mind. If liver is not smooth and spleen is not smooth, phlegm-heat disturbing the interior, gallbladder is abnormal, and the force of mind and resolution is reduced, symptoms such as timidity, anxiety, terrorism and easy convulsion appear.
The traditional Chinese medicine composition provided by the invention is prepared by taking liver and spleen harmonizing, phlegm eliminating, dampness resolving, middle-jiao regulating and nerve soothing as an entry point, taking Ming-Xue Ji Jiawei Xiaoyao san from medical abstract and Songchen Wen Dan Tang from Sanyuan Ji Yi disease theory, adding dragon bone and oyster, and the Jiawei Xiaoyao san has the effects of soothing liver, strengthening spleen, clearing heat and nourishing blood, warming bile soup and regulating qi and reducing phlegm, and clearing gallbladder and harmonizing stomach. The liver, the gallbladder, the spleen and the stomach are all viscera which are exterior-interior, the modified leisure and the dispersing function are used for treating the viscera to regulate the liver and the spleen, the warm gallbladder soup is used for treating the viscera to regulate the gallbladder and the stomach, the two are combined, the liver is soothing to facilitate the gallbladder qi, clear the gallbladder to relieve liver depression, the spleen is strengthening to facilitate the stomach to reduce the stomach, the stomach is harmonized to promote spleen lifting, the viscera diseases are treated to treat the viscera, the viscera is treated to treat the viscera with the same effects of soothing the liver and strengthening the spleen, clearing the gallbladder and the stomach, and the fossil fragments and the oyster are used for suppressing the nerves to calm the stomach, so the soup is especially suitable for people with depression due to liver depression and spleen deficiency, incoordination between the gallbladder and the stomach and phlegm dampness stagnation. In the recipe, bupleurum root, radix bupleuri, which is used as a monarch drug, is used for soothing liver and relieving depression, and pinellia tuber, which is used for eliminating dampness and resolving phlegm, and harmonizing stomach and lowering adverse qi, is used for soothing liver and relieving depression, and is matched with the liver and the pinellia tuber, the liver and the qi are smooth, and the qi movement of the body is smooth when the liver and the middle energizer are smooth, and the bupleurum root can raise clear yang of spleen and stomach, the pinellia tuber can lower turbid qi of the middle energizer, and the bupleurum root, the pinellia tuber and the pinellia tuber are matched with each other, and the bupleurum root has the effects of raising clear and lowering turbid; the 4 medicines of white paeony root, bamboo shavings, immature bitter orange and stir-fried bighead atractylodes rhizome are taken as ministerial medicines; white peony root is sour, bitter and slightly cold, nourishes blood, astringes yin, softens liver and is used together with bupleurum, nourishes liver and helps liver, blood harmonizes liver and harmonizes liver, blood fills liver and softens liver, so that liver is softened and liver qi reaches; the bamboo Ru Qing gall is matched with the purified pinellia tuber, so that not only can the phlegm be reduced and the stomach be harmonized, but also the gall heat can be cleared, and the gall qi is cleared, so that the phlegm heat is removed and the gall qi is fixed; fructus Aurantii Immaturus has effects of removing qi stagnation, eliminating phlegm, and resolving masses, and can be used together with bupleuri radix, for improving qi-flowing and resolving stagnation, and with rhizoma Pinelliae Preparata for improving qi-flowing and resolving phlegm; the stir-fried bighead atractylodes rhizome can invigorate spleen and replenish qi, liver diseases are most likely to transmit spleen, and wood depression causes soil failure, so that the bighead atractylodes rhizome can invigorate spleen qi, not only can the soil be used for defending wood multiplication, but also nutrient and blood biochemically and actively; the 7 medicines of angelica, moutan bark, gardenia, dried orange peel, tuckahoe, dragon bone and oyster are taken as adjuvant medicines; angelica sinensis is sweet, pungent, bitter and warm, and nourishes and harmonizes blood; cortex moutan has effects of clearing pathogenic fire in blood, fructus Gardeniae has effects of clearing liver and gallbladder stagnation heat, and inducing heat downward; pericarpium Citri Reticulatae is pungent and bitter and warm, and has effects of regulating qi-flowing, removing stagnation, eliminating dampness and phlegm; poria has effects of invigorating spleen, eliminating dampness, tranquilizing mind, strengthening spleen and stomach, eliminating turbid dampness, and relieving restlessness by Du Shengtan source, promoting qi and blood generation; the dragon bone calms and calms the nerves, calms sweat and arrest spontaneous emission, and relieves liver depression and qi stagnation; oyster has the functions of relieving uneasiness, calming liver, suppressing yang hyperactivity and regulating emotion; the honey-fried licorice root and the mint 2 medicines are combined into a guiding drug; the honey-fried licorice root has the effects of tonifying qi, strengthening the middle-jiao, relieving liver urgency and harmonizing various medicines; a small amount of herba Menthae is added to dispel qi stagnation and promote the transmission of liver channel stagnated heat. The whole prescription contains 15 medicines, and the medicines are used together for regulating liver and spleen, eliminating dampness and phlegm, regulating middle warmer and soothing nerves, and regulating cold temperature and dredging and nourishing. The main indications are: stagnation syndrome due to liver-qi stagnation, spleen deficiency, incoordination between gallbladder and stomach, and stagnation of phlegm-dampness. Can be used for treating depression, anxiety, climacteric syndrome, neurasthenia, neurosis, hysteria, amnesia, insomnia, separation disorder (Sunstruct), premenstrual tension, acute and chronic gastritis, and gastroesophageal reflux, etc., with syndrome differentiation of liver depression, spleen deficiency, incoordination between gallbladder and stomach, and stagnation of phlegm and dampness.
The traditional Chinese medicine composition provided by the invention is safe, quick in effect, good in treatment effect, free of toxic and side effects, easy to accept by patients and capable of avoiding toxic and side effects caused by using western medicines in large doses. Meanwhile, compared with basic Fang Wendan soup and Danzhi Xiaoyao powder, the traditional Chinese medicine composition provided by the invention has a better treatment effect on depression caused by liver depression and spleen deficiency and excessive dampness.
Drawings
FIG. 1 is a graph of open field test results;
FIG. 2 is a graph of tail-suspension test results; in contrast to the normal group, ** P<0.01, compared with the warm bladder Shang Zu, ## P<0.01; compared with the Danzhi Xiaoyao powder group, $ P<0.05；
FIG. 3 is a graph of forced swim test results; in contrast to the warm bladder Shang Zu, # P<0.05， ## P<0.01; compared with the Danzhi Xiaoyao powder group, $ P<0.05。
Detailed Description
The present invention will now be described in detail with reference to the drawings and specific examples, which should not be construed as limiting the invention. Unless otherwise indicated, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples are commercially available unless otherwise indicated.
Based on the characteristics of the pathogenesis of depression with liver depression and spleen deficiency and excessive dampness, the invention provides a traditional Chinese medicine composition for treating depression, which takes 'liver and spleen are synchronous, phlegm is removed, dampness is removed, middle-jiao is regulated and tranquillization' as an access point, and is prepared from the following raw materials in parts by weight: 6-20 parts of purified pinellia tuber, 6-20 parts of bupleurum, 6-20 parts of white peony root, 6-20 parts of bamboo shavings, 6-30 parts of immature bitter orange, 6-30 parts of stir-fried bighead atractylodes rhizome, 6-20 parts of Chinese angelica, 6-20 parts of tree peony bark, 6-20 parts of cape jasmine, 6-20 parts of dried orange peel, 6-20 parts of poria cocos, 9-30 parts of dragon bone, 9-30 parts of oyster, 3-15 parts of peppermint and 6-20 parts of honey-fried licorice root.
The Chinese medicinal composition is decocted with water for administration, one dose is taken every day, 2 times a day, each time in the morning and evening, and is taken after meals for 30 to 60 minutes with 200 to 300ml each time.
The main indications of the traditional Chinese medicine composition are: depression with liver depression and spleen deficiency and excessive dampness.
Efficacy: liver soothing, qi regulating, dampness eliminating, gallbladder heat clearing and stomach harmonizing
The main indications are: stagnation syndrome due to liver-qi stagnation, spleen deficiency, incoordination between gallbladder and stomach, and stagnation of phlegm-dampness. Modern times are commonly used for depression, anxiety, climacteric syndrome, neurasthenia, neurosis, hysteria, amnesia, insomnia, separation disorder (Gastrodia-Bluestone), premenstrual tension, acute and chronic gastritis, gastroesophageal reflux and the like, and the syndrome differentiation is the condition of liver depression, spleen deficiency, incoordination between gallbladder and stomach, phlegm-dampness stagnation.
Common symptoms: low emotion, reduced interest, chest distress, insomnia, dysphoria, irritability, tension, easy convulsion, anorexia, listlessness, pain, pale red tongue, thin and white coating, and wiry pulse.
The traditional Chinese medicine composition can be further prepared into pharmaceutically acceptable oral preparations, such as granules, capsules, tablets, oral liquid, syrup and the like.
Formulations for oral administration may contain usual adjuvants such as binders, fillers, diluents, lubricants, disintegrants, colorants, flavoring agents and wetting agents, and if necessary, tablets may be coated. Optional fillers include cellulose, mannitol, lactose and other similar fillers. Alternative disintegrants include starch, polyvinylpyrrolidone and starch derivatives, such as sodium starch glycolate. An optional lubricant such as magnesium stearate. Optional humectants include sodium dodecyl sulfate.
Oral liquid preparations are in the form of suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid formulations may include conventional additives such as suspending agents, for example, glycerin, syrup, methylcellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like; emulsifying agents, for example lecithin or acacia; nonaqueous carriers, such as almond oil, fractionated coconut oil, propylene glycol or ethyl alcohol; preservatives, for example, methylparaben, propylparaben or sorbic acid; conventional flavoring or coloring agents may also be included.
The following describes the traditional Chinese medicine composition provided by the invention with reference to specific examples.
Example 1
A traditional Chinese medicine composition for treating depression is prepared from the following raw materials: 15g of purified pinellia tuber, 10g of bupleurum, 15g of white peony root, 15g of bamboo shavings, 20g of immature bitter orange, 20g of stir-fried bighead atractylodes rhizome, 10g of Chinese angelica, 15g of tree peony bark, 10g of gardenia, 20g of dried orange peel, 15g of poria cocos, 30g of dragon bone, 30g of oyster, 6g of peppermint and 10g of honey-fried licorice root.
Example 2
A traditional Chinese medicine composition for treating depression is prepared from the following raw materials:
6g of purified pinellia tuber, 6g of bupleurum, 6g of white paeony root, 6g of bamboo shavings, 6g of immature bitter orange, 6g of stir-fried bighead atractylodes rhizome, 6g of Chinese angelica, 6g of tree peony bark, 6g of gardenia, 6g of dried orange peel, 6g of tuckahoe, 9g of dragon bone, 9g of oyster, 3g of peppermint and 6g of honey-fried licorice root.
Example 3
A traditional Chinese medicine composition for treating depression is prepared from the following raw materials:
20g of purified pinellia tuber, 20g of bupleurum, 20g of white peony root, 20g of bamboo shavings, 30g of immature bitter orange, 30g of stir-fried bighead atractylodes rhizome, 20g of Chinese angelica, 20g of tree peony bark, 20g of gardenia, 20g of dried orange peel, 20g of poria cocos, 30g of dragon bone, 30g of oyster, 15g of peppermint and 20g of honey-fried licorice root.
Example 4
A traditional Chinese medicine composition for treating depression is prepared from the following raw materials:
12g of purified pinellia tuber, 12g of bupleurum, 18g of white peony root, 18g of bamboo shavings, 15g of immature bitter orange, 15g of stir-fried bighead atractylodes rhizome, 18g of Chinese angelica, 18g of tree peony bark, 15g of gardenia, 15g of dried orange peel, 18g of poria cocos, 20g of dragon bone, 20g of oyster, 8g of peppermint and 12g of honey-fried licorice root.
Example 5
A traditional Chinese medicine composition for treating depression is prepared from the following raw materials:
18g of purified pinellia tuber, 10g of bupleurum, 12g of white peony root, 12g of bamboo shavings, 10g of immature bitter orange, 25g of stir-fried bighead atractylodes rhizome, 12g of Chinese angelica, 18g of tree peony bark, 12g of gardenia, 18g of dried orange peel, 12g of poria cocos, 25g of dragon bone, 18g of oyster, 12g of peppermint and 15g of honey-fried licorice root.
The traditional Chinese medicine compositions provided in the above examples 1 to 5 are prepared according to the following method:
weighing purified pinellia tuber, bupleurum, white peony root, bamboo shavings, immature bitter orange, fried bighead atractylodes rhizome, angelica, moutan bark, gardenia, dried orange peel, poria cocos, dragon bone, oyster, peppermint and honey-fried licorice root for standby;
mixing the weighed medicinal materials, adding water which is 8 times of the total amount of the medicinal materials for decocting for 1.5 hours for the first time, filtering, collecting the first decoction, adding water which is 6 times of the total amount of the filter residues for decocting for 1.5 hours, filtering, collecting the second decoction, and combining the two decoctions.
Example 6
The traditional Chinese medicine composition for treating depression is different from the embodiment 1 only in the preparation method, and specifically comprises the following steps:
weighing purified pinellia tuber, bupleurum, white peony root, bamboo shavings, immature bitter orange, fried bighead atractylodes rhizome, angelica, moutan bark, gardenia, dried orange peel, poria cocos, dragon bone, oyster, peppermint and honey-fried licorice root for standby;
mixing the weighed medicinal materials, adding water which is 8 times of the total amount of the medicinal materials for decocting for 1.0h for the first time, filtering, collecting the first decoction, adding water which is 6 times of the total amount of the filter residues for decocting for 1.0h for the filter residues, filtering, collecting the second decoction, and combining the two decoctions to obtain the traditional Chinese medicine.
Example 7
A traditional Chinese medicine granule for treating depression is prepared by the following method:
weighing 15g of purified pinellia tuber, 10g of bupleurum, 15g of white peony root, 15g of bamboo shavings, 20g of immature bitter orange, 20g of fried bighead atractylodes rhizome, 10g of Chinese angelica, 15g of tree peony bark, 10g of cape jasmine, 20g of dried orange peel, 15g of poria cocos, 30g of dragon bone, 30g of oyster, 6g of peppermint and 10g of honey-fried licorice root;
mixing the weighed medicinal materials, adding 8 times of water corresponding to the total amount of the medicinal materials for decocting for 1.0h for the first time, filtering, collecting the first decoction, adding 6 times of water corresponding to the total amount of the filter residues for decocting for 1.0h for filtering, collecting the second decoction, combining the two decoctions, concentrating to have the relative density of 1.10 (70 ℃) at 50 ℃, -0.06 to-0.08 mpa, standing, centrifuging, concentrating the supernatant to have the relative density of 1.25 (70 ℃), adding 0.5 times of sugar powder and 1.5 times of soluble starch into the obtained concentrate, uniformly mixing, granulating, setting the temperature of a hot air circulation oven to be 70 ℃, drying to have the water content of about 6%, granulating, and packaging to obtain the medicine for treating depression in a granule form. Packaging specification: 15 g/bag, 10 bags/box.
Experimental example 1
1. Laboratory animals and groups
70 SPF-class male ICR mice, 6-8 w, 18-20 g weight, all animals drink water freely, and are fed in 24h light and dark period environment, 12h day and night, the temperature (25+/-2) DEG C and the relative humidity of 40-60%.
2. Method of
After the mice were fed adaptively for 3 to 7 days, they were randomly divided into normal group (normal saline), fluoxetine group (2 g/kg.d), wintergreen soup group (crude drug amount 31.7 g/kg.d), danzhixiaoyao powder group (crude drug amount 37 g/kg.d), example 1 high dose group (crude drug amount 120.6 g/kg.d), example 1 low dose group (crude drug amount 60.3 g/kg.d), example 1 low dose group (crude drug amount 30.15 g/kg.d), normal group was administered with normal saline lavage, 10 groups each, and 15 days of continuous administration were performed, and behavioral tests including Open Field Test (OFT), tail Suspension Test (TST), forced Swimming Test (FST) were performed after the last administration for 1 hour.
The medicine composition of the warm biliary soup comprises the following components: 15g of purified pinellia tuber, 15g of bamboo shavings, 20g of stir-fried immature bitter orange, 20g of dried orange peel, 15g of poria cocos, and 10g of honey-fried licorice root.
The medicine composition of the Danzhi Xiaoyao powder comprises the following components: 10g of bupleurum, 10g of angelica, 15g of stir-fried white peony root, 15g of poria cocos, 20g of stir-fried bighead atractylodes rhizome, 15g of tree peony bark, 10g of raw gardenia, 10g of honey-fried licorice root and 5g of peppermint.
2.1 Open Field Test (OFT)
The method is characterized in that the method is carried out in a quiet environment, animals are placed in small squares with the height of 30-40cm, the bottom edge length is 100cm, the black inner wall is divided into 4 small squares with the bottom edge of 25cm, the animals are placed in the center of the bottom surface in the box, shooting and timing are carried out at the same time, stopping after 5min, and the inner wall and the bottom surface of the square box are cleaned so as to prevent the information (such as the urine and the smell of the animals) remained in the last time from influencing the next test result. The number of voluntary activities of the mice was determined during the test.
2.2 Tail Suspension Test (TST)
The position 2cm behind the tail of the rat is fixed at a horizontal position by using an adhesive tape, so that the rat is in an inverted hanging state, the head is about 6-8 cm away from the lower horizontal plane, and the tired-in time of the animal after 4min within 6min is recorded.
2.3 Forced Swimming Test (FST)
The rat is placed in a glass jar with the height of 40cm and the diameter of 30cm and containing tap water at 25 ℃, the water depth is adjustable, the rat is just enough to touch the bottom of the cylinder but not enough to support the body, and the accumulation and immobility time of the animal within 6min after 4min is recorded.
3. Results
The number of independent activities of mice measured in the OFT indicates the independent activity capacity of the mice, and the independent activity numbers of the mice after each group of administration are not different, which indicates that the mice are normal mice and the independent activity capacity of the mice is not affected after administration, as shown in fig. 1.
TST is a model of the fact that a mouse attempts to escape but cannot escape after tail suspension, so as to give up struggling and enter a specific depression immobility state, and the typical "immobility state" exhibited by animals is called a destiny state, and the depression state of the animals is estimated by recording the immobility time of the animals in a specific time period during an experiment, and the longer the immobility time, the more serious the depression degree. The results show that the low and medium dose groups of example 1 significantly shortened the immobility time of the mice, see figure 2.
The FST also records the immobility time of the mice in a limited environment to try to escape but not escape, so as to give up the struggling time to enter the immobility state, and the longer the immobility time, the more serious the depression. The results show that the low dose group of example 1 significantly reduced the immobility time of the mice, see figure 3.
The data of OFT, TST, FST shows that the effects of the low and medium dose groups of the example 1 are better than those of the Wen Dan Tang group and Dan Zhi Xiaoyao san group, but the low dose of the example 1 is finally determined to be the optimal dose by considering the influence of the concentration of the drug on the administration, the drug concentration is low, the animal acceptance is high and the animal acceptance is not counteracted.
Experimental example 2
Clinical data
1. Case sources
60 patients were selected from the first affiliated hospital of Henan traditional Chinese medicine university, henan province middle hospital, henan traditional Chinese medicine university and the third affiliated hospital clinic of Henan from 1 month in 2016 to 8 months in 2020. Subjects were randomly selected into treatment and control groups, 30 groups each were treated for 35 days, screened separately, rated on the effectiveness index scale at baseline, treatment 7, 14, 21, 28, 35 days, and compared for the two groups of efficacy, onset time, adverse effects after dosing.
2. Diagnostic criteria
2.1 Western medicine diagnostic criteria
Western medicine diagnosis Standard refers to the diagnosis Standard for depression of the third edition (CCMD-3) of the Chinese mental disease Classification scheme and diagnosis Standard: the main characteristic of the low emotion is that the emotion is stuffy or sad and is continuous for two weeks, and four of the following symptoms are also involved:
(1) Obvious decline of energy and no cause of continuous fatigue;
(2) Too low self-assessment, or self-responsibility, or feelings of guilt;
(3) Mental retardation or agitation;
(4) Losing interest in daily life and having no pleasant feeling;
(5) Repeatedly appearing thinking of death or suicide;
(6) Difficulty in association, and significantly reduced subjective thinking ability;
(7) Inappetence and obvious weight loss;
(8) The sexual desire is obviously reduced;
(9) Insomnia or hypersomnia.
Serious standard: the social function is impaired, causing pain or adverse consequences to the person.
Disease course criteria:
(1) Compliance with symptomatic and severe standards has been sustained for at least 2 weeks.
(2) Certain schizophrenic symptoms may exist, but are not in line with diagnosis of schizophrenic disease. If the symptom criteria of the schizophrenia are met at the same time, the depressive episode criteria are met for at least 2 weeks after the alleviation of the schizophrenia.
Exclusion criteria: removing organic mental disorder, or mental disorder caused by psychoactive substances and non-addictive substances.
2.2 Western medicine scoring criteria
Was performed using hamilton depression scale (HAMD) scoring method.
The HAMD project uses a 3-5 scale score of 0-4: 0 is no, 1 is mild, 2 is moderate, 3 is severe, and 4 is extremely severe.
Depression emotion: 0 point: the method is free; 1, the method comprises the following steps: complaints only when the inquiry is up; 2, the method comprises the following steps: spontaneously expressed in conversation; 3, the method comprises the following steps: the emotion can be revealed from expression, posture, sound or crying without speaking; 4, the following steps: the spontaneous language of the patient, and thus the non-verbal expression (action, expression), almost fully represents this emotion.
The sense of crime is: 0 point: the method is free; 1, the method comprises the following steps: blame oneself, feel oneself and involve others; 2, the method comprises the following steps: consider itself criminally or repeatedly think about past mistakes and errors; 3, the method comprises the following steps: the current disease is considered to be the most own wrong punishment or criminal sense; 4, the following steps: criminal delusions are accompanied by a hallucination or threatening illusion
And (3) suicide: 0 point: the method is free; 1, the method comprises the following steps: it is felt to be alive without meaning; 2, the method comprises the following steps: hope that oneself has died, or think about it often; 3, the method comprises the following steps: negative concept (suicidal thoughts); 4, the following steps: criminal delusions are accompanied by a hallucination or threatening illusion.
Difficulty falling asleep: 0 point: the method is free; 1, the method comprises the following steps: the complaints sometimes have difficulty falling asleep, namely, the complaints still cannot fall asleep for half an hour after getting on bed; 2, the method comprises the following steps: the complaints have difficulty falling asleep every night.
Sleep is not deep: 0 point: the method is free; 1, the method comprises the following steps: light sleep and dreaminess; 2, the method comprises the following steps: the night (12 late before) was awakened (without the toilet).
Early wake up: 0 point: the method is free; 1, the method comprises the following steps: has early wake-up, is 1 hour earlier than usual, but can fall asleep again; 2, the method comprises the following steps: and the patient cannot fall into the cup again after waking early.
Work and interest: 0 point: the method is free; 1, the method comprises the following steps: the inquiry is only carried out when the inquiry is carried out; 2, the method comprises the following steps: spontaneously expressing, directly or indirectly, that interest in activities, work or learning is lost, such as feeling unqualified, melancholy is pending, unable to persist or need to force oneself to work or activity; 3, the method comprises the following steps: the activity time is reduced or the effect is reduced, and the inpatients participate in the ward labor or entertainment activities for less than 3 hours every day; 4, the following steps: the resident can not take part in any activity or can not complete the daily business of the ward without the help of other people because the resident stops working due to the current diseases.
Delay: 0 point: the method is free; 1, the method comprises the following steps: mild retardation was found in mental examination; 2, the method comprises the following steps: mental examination found significant retardation; 3, the method comprises the following steps: mental examination is difficult to perform; 4, the following steps: the question (stuffy) cannot be answered at all.
The step of shock: 0 point: the method is free; 1, the method comprises the following steps: some mind was not calm during the examination; 2, the method comprises the following steps: obvious restlessness or little movement; 3, the method comprises the following steps: unable to sit still, once standing up during the examination; 4, the following steps: hand rubbing, finger biting, hair pulling and lip crossing.
Mental anxiety: 0 point: the method is free; 1, the method comprises the following steps: questions and time complaints; 2, the method comprises the following steps: spontaneously expressed; 3, the method comprises the following steps: expression and talk flow are a significant concern; 4, the following steps: obvious panic.
Somatic anxiety: physiological symptoms of anxiety include dry mouth, abdominal distension, diarrhea, abdominal pain, palpitations, headache, excessive ventilation and sigh, as well as frequent urination and sweating. 0 point: the method is free; 1, the method comprises the following steps: light weight; 2, the method comprises the following steps: moderate, with positive symptoms as described above; 3, the method comprises the following steps: severe, the symptoms are severe, affecting the symptoms or requiring additional treatment for 4 points: severely affecting life and activity.
Gastrointestinal symptoms: 0 point: the method is free; 1, the method comprises the following steps: anorexia, but no need for others to encourage self-feeding; 2, the method comprises the following steps: the need for feeding requires others to promote or request or to apply laxatives or digestion aids.
Systemic symptoms: 0 point: the method is free; 1, the method comprises the following steps: heavy feeling of limbs, back or neck, back pain, headache, muscle pain, general debilitation or tiredness; 2, the method comprises the following steps: the symptoms are remarkable.
Sex symptoms: refers to hyposexuality, menorrhea, etc. 0 point: the method is free; 1, the method comprises the following steps: light weight; 2, the method comprises the following steps: a severe degree; 3, the method comprises the following steps: cannot be affirmed, or the item does not fit the subject (does not take into account the total score).
Suspicion: 0 point: the method is free; 1, the method comprises the following steps: excessive physical attention; 2, the method comprises the following steps: repeatedly considering health problems; 3, the method comprises the following steps: delusions of suspicious diseases; 4, the following steps: fanciful suspicion accompanied by fanciful party.
Weight loss: 0 point: the method is free; 1, the method comprises the following steps: weight loss is more than 1 jin in one week; 2: weight loss of more than 2 jin in one week
Self-aware force: 0 point: the method is free; 1, the method comprises the following steps: knowing that there is disease, it is manifested as depression; 2, the method comprises the following steps: knowing that the patient has a disease, but is due to poor partner food, environmental problems, busy work, virus infection or need to rest and the like; 3, the method comprises the following steps: the disease is completely denied.
2.3 diagnostic criteria for TCM
According to the traditional Chinese medicine diagnosis standard and syndrome standard formulated in 1995 'traditional Chinese medicine syndrome diagnosis curative effect standard depression disease'. The diagnosis basis is as follows: (1) Symptoms such as depression, lassitude, chest distress, hypochondriac distention, frequent sighing, anorexia, insomnia, dreaminess, irritability, frequent crying, etc.; (2) there are depression and anger and anxiety. Sadness. History of emotional injury such as sadness; (3) Organic diseases can be excluded through various system examinations and laboratory examinations.
2.4 dialectical criteria of Chinese medicine
The method is formulated by referring to SFDA (Small form factor) guidelines for clinical study of new traditional Chinese medicines (2005 edition), traditional Chinese medicine clinical path and traditional Chinese medicine diagnosis and treatment scheme (2017 edition) of the traditional Chinese medicine administration' depression (depressive episode).
The definition of patients with liver depression and spleen deficiency and phlegm obstruction is as follows:
main symptoms are as follows: low emotion, distention and discomfort in chest and hypochondrium, frequent anxiety and frequent sighing;
secondary symptoms: emaciation, anorexia, insomnia, amnesia, chest distress, gastrectasia, abdominal pain, abdominal distention, loose stool, discomfort in throat, irritability, belch, singultus, restlessness, and body pain;
tongue appearance: pale red tongue with white and greasy coating;
pulse condition: the string is slipped.
Meets the diagnosis standards of depression western medicine depression and traditional Chinese medicine depression, has 3 main symptoms and 3 secondary symptoms of the traditional Chinese medicine with liver depression and spleen deficiency and phlegm obstruction, and can diagnose depression with liver depression and spleen deficiency and phlegm obstruction by referring to tongue and pulse.
2.5 Chinese medical symptom scoring criteria
Making by referring to the guidelines of clinical research on new Chinese medicine
Main symptoms are as follows:
depression of emotion: 0 point: the method is free; 2, the method comprises the following steps: sometimes occurs; 4, the following steps: frequently occurring but still capable of self-controlling; and 6, dividing: frequent occurrence is that the medicine needs to be taken for treatment.
Principal to crie: 0 point: the method is free; 2, the method comprises the following steps: sometimes, the person is commissioned to cry; 4, the following steps: often crying, the patient can still control; and 6, dividing: the person can not control the cry.
Good-for-rest: 0 point: the method is free; 2, the method comprises the following steps: sometimes there is a Tai Chi; 4, the following steps: the method is performed in the time of the Tai Chi; and 6, dividing: the Taiji frequency is used.
Fullness in chest and hypochondrium: 0 point: the method is free; 2, the method comprises the following steps: occasionally, the self-alleviating effect can be achieved; 4, the following steps: the chest and hypochondrium is full for about 2 hours every day; and 6, dividing: and the chest and hypochondrium is continuously full.
Secondary symptoms:
forgetfulness: 0 point: normal memory; 1, the method comprises the following steps: forgetting; 2, the method comprises the following steps: often forget; 3, the method comprises the following steps: often forget to do so.
Insomnia: 0 point: normal; 1, the method comprises the following steps: sleep is awake or sleepy without reality. Early morning wake, and no influence on work; 2, the method comprises the following steps: sleep for less than 4 hours every day, so that normal work is difficult to adhere to; 3, the method comprises the following steps: the people can not sleep at night, and the normal work is difficult to adhere to.
Irritability: 0 point: the method is free; 1, the method comprises the following steps: emotional agitation; 2, the method comprises the following steps: is easy to be irritated; 3, the method comprises the following steps: more than 10 times daily.
Belching: 0 point: the method is free; 1, the method comprises the following steps: more than 3 times daily; 2, the method comprises the following steps: 4-9 times daily; 3, the method comprises the following steps: more than 10 times daily.
Hiccup: 0 point: the method is free; 1, the method comprises the following steps: more than 3 times daily; 2, the method comprises the following steps: 4-9 times daily; 3, the method comprises the following steps: more than 10 times daily.
Restlessness of sitting and lying down): 0 point: the method is free; 2, the method comprises the following steps: restless sitting and lying.
Feeling of foreign body in pharynx: 0 point: the method is free; 2, the method comprises the following steps: has foreign body sensation.
Body pain: 0 point: the method is free; 2, the method comprises the following steps: body pain.
Chest distress: 0 point: the method is free; 1, the method comprises the following steps: occasionally, the self-alleviating effect can be achieved; 2, the method comprises the following steps: the stomach is stuffiness for about 2 hours each day; 3, the method comprises the following steps: and is persistent.
3. Inclusion criteria
(1) Meets the diagnosis standard of Western depression;
(2) Meets the diagnosis standard of traditional Chinese medicine depression syndrome and the diagnosis standard of liver depression and spleen deficiency phlegm obstruction syndrome;
(3) HAMD score is more than or equal to 7 and less than or equal to 24;
(4) Age is more than or equal to 18 years old and less than or equal to 75 years old;
(5) The mind is clear, no language disorder exists, the symptom of the user can be correctly expressed, and the user can agree with the knowledge;
(6) Patient compliance is high, can cooperate to accomplish this study.
The selected cases must meet the 6 inclusion criteria above at the same time
4. Exclusion criteria
(1) Those who had taken antidepressants within the first 1 month of the enrollment;
(2) Patients with major depression or those with a major suicidal tendency;
(3) Those with secondary depressive episodes or with severe psychotic symptoms;
(4) Patients with bipolar disorder or refractory depression;
(5) Patients under 18 years old or over 75 years old, pregnant women or lactating women;
(6) Combining serious primary diseases of various systems or heart, liver and kidney functional insufficiency;
(7) Allergic to the known study drug ingredients.
The case of the above 1 is excluded
5. Case rejection and shedding criteria
(1) Patient compliance is poor, and patients who do not take medicines according to the regulations;
(2) The serious adverse reaction and other conditions occur in the process of taking the medicine, other related treatments are needed, the medicine cannot be continuously taken according to the regulations, or the illness state of the patient is further worsened in the test process, and other treatments are needed;
(3) The observation result is possibly influenced by taking other medicines during taking;
(4) A self-exit for some reason;
(5) A follow-up failed to be accepted for some reason;
6. treatment regimen
6.1, treatment grouping:
patients were randomized into 2 groups, 30 control groups, 30 treatment groups.
6.2 methods of treatment
Treatment group: the traditional Chinese medicine composition provided in the embodiment 1 of the invention is used for treatment, and the prescription mainly comprises the following components: 15g of purified pinellia tuber, 10g of bupleurum, 15g of white peony root, 15g of bamboo shavings, 20g of immature bitter orange, 20g of stir-fried bighead atractylodes rhizome, 10g of Chinese angelica, 15g of tree peony bark, 10g of gardenia, 20g of dried orange peel, 15g of poria cocos, 30g of dragon bone, 30g of oyster, 6g of peppermint and 10g of honey-fried licorice root. The traditional Chinese medicine composition decoction is taken for treating the patients with the depression with the syndrome of liver depression and spleen deficiency and phlegm obstruction, is decocted with water for taking the decoction for 2 times a day, is taken once a day in the morning and at night, is taken for 30 to 60 minutes after meal, and is 200 to 300ml each time. 7 days is a treatment course, and 5 treatment courses are counted for curative effect.
Control group: paroxetine hydrochloride tablets (produced by Beijing Fuyuan medicine Co., ltd., oral administration, 20 mg/tablet), 20 mg/time, 1 time/day, and taken after meal. 7 days is a treatment course, and 5 treatment courses are counted to obtain the total curative effect.
7. Efficacy index and evaluation criteria
7.1 Western medicine efficacy index
HAMD total score decrease = baseline HAMD total score-post-treatment HAMD total score;
HAMD total score decrease rate = [ (baseline HAMD total score-post-treatment HAMD total score)/(baseline HAMD total score ] ×100% (see standard formulation of treatment efficacy for depression by the chinese medical society in 1984)
(1) Evaluation criteria:
and (3) healing: HAMD score is less than or equal to 7;
significant progress: the percent reduction is more than or equal to 50 percent;
progress: the percent reduction is more than or equal to 25 percent;
invalidation: the percent reduction is less than 25 percent,
significant = healing + significant improvement + progress.
(2) Efficacy evaluation criteria: the decrease value and decrease rate of HAMD at the end of treatment were used as efficacy evaluation criteria, and the end of evaluation was at the end of day 35.
7.2 evaluation index of Chinese medical symptom curative effect
Total score of symptoms of traditional Chinese medicine = baseline total score of symptoms of traditional Chinese medicine-total score of symptoms of traditional Chinese medicine after treatment;
total score of symptoms of traditional Chinese medicine = [ (total score of symptoms of traditional Chinese medicine baseline-total score of symptoms of traditional Chinese medicine after treatment +.100%; (assessment using nimodipine method)
(1) Evaluation criteria:
clinical control: the clinical symptoms and signs disappear or disappear basically, and the integral of symptoms is reduced by more than or equal to 90 percent;
the effect is shown: the clinical symptoms and signs are obviously improved, and the integral of symptoms is reduced by more than or equal to 70 percent;
the method is effective: the clinical symptoms and signs are improved, and the integral of symptoms is reduced by more than or equal to 30 percent;
invalidation: the clinical symptoms and signs are not obviously improved or even aggravated, and the integral of symptoms is reduced by less than or equal to 30 percent.
Total effective = clinical control + onset + effective
Efficacy evaluation criteria: the decrease rate of the symptoms of the traditional Chinese medicine at the treatment end is taken as a curative effect evaluation standard, and the evaluation end point is at the end of 35 days.
8. Evaluation of efficacy
Of 60 patients, 22 men and 38 women have a ratio of 1:1.73, and the ages of men and women are 18 to 75 years, and the course of the disease is 35 to 10 years, 7 days of treatment is a treatment course, and the curative effect of the treatment is mainly observed within 35 days (five treatment courses).
9. Results
The results of the treatment were assessed by the western medicine HAMD score efficacy, as shown in table 1.
TABLE 1 efficacy of HAMD reduction in groups
| Grouping | Number of examples | Healing (example) | Significant progress (example) | Progress (example) | Invalidation (example) | Obvious effect (%) |
| Treatment group | 30 | 6 | 16 | 4 | 4 | 86.67 |
| Control group | 30 | 4 | 14 | 6 | 6 | 80.00 |
The therapeutic results were assessed by scoring efficacy of symptoms in TCM, as shown in Table 2.
Table 2 scoring efficacy of symptoms in each group of chinese medicine
As can be seen by comparison, whether the Western medicine HAMD score evaluation or the traditional Chinese medicine symptom score evaluation is adopted, the total effective rate and the clinical control rate of the treatment group at the end of treatment are obviously higher than those of the control group, and the treatment effect of the treatment group on depression caused by liver depression and spleen deficiency and dampness is obviously better than that of the control group.
Safety: the adverse reaction is rarely seen in the treatment group during the administration period, and the reactions such as nausea, abdominal distention, diarrhea and the like are occasionally caused, and are not obvious; the control group has more adverse reactions and symptoms such as nausea, vomiting, anorexia, palpitation, diarrhea, abdominal distension and the like, and the adverse reactions of the treatment group are obviously less than those of the control group in general.
In conclusion, the traditional Chinese medicine composition provided by the invention has obvious and stable curative effect on depression caused by liver depression and spleen deficiency and phlegm obstruction, is safe to use, has great clinical significance and is worthy of popularization and application.
While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. It is therefore intended that the following claims be interpreted as including the preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
It will be apparent to those skilled in the art that various modifications and variations can be made to the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention also include such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims (9)
1. The traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness is characterized by being prepared from the following raw materials in parts by weight: 6-20 parts of purified pinellia tuber, 6-20 parts of bupleurum, 6-20 parts of white peony root, 6-20 parts of bamboo shavings, 6-30 parts of immature bitter orange, 6-30 parts of stir-fried bighead atractylodes rhizome, 6-20 parts of Chinese angelica, 6-20 parts of tree peony bark, 6-20 parts of cape jasmine, 6-20 parts of dried orange peel, 6-20 parts of poria cocos, 9-30 parts of dragon bone, 9-30 parts of oyster, 3-15 parts of mint and 6-20 parts of honey-fried licorice root.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 15 parts of purified pinellia tuber, 10 parts of bupleurum, 15 parts of white peony root, 15 parts of bamboo shavings, 20 parts of immature bitter orange, 20 parts of stir-fried bighead atractylodes rhizome, 10 parts of Chinese angelica, 15 parts of tree peony bark, 10 parts of gardenia, 20 parts of dried orange peel, 15 parts of poria cocos, 30 parts of dragon bone, 30 parts of oyster, 6 parts of peppermint and 10 parts of honey-fried licorice root.
3. A method for preparing a traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness according to claim 1 or 2, which is characterized by comprising the following steps:
weighing purified pinellia tuber, bupleurum, white paeony root, bamboo shavings, immature bitter orange, stir-fried bighead atractylodes rhizome, chinese angelica, moutan bark, gardenia, dried orange peel, tuckahoe, dragon bone, oyster, peppermint and honey-fried licorice root according to parts by weight for standby;
mixing the weighed medicinal materials, decocting in water, and collecting decoction to obtain the traditional Chinese medicine composition.
4. A method according to claim 3, wherein the specific process of decocting in water is as follows: adding water which is 6-8 times of the total amount of the medicinal materials into the mixed medicinal materials, decocting for 2-3 times, 1.0-1.5 h each time, mixing the decoctions, and filtering.
5. The use of the traditional Chinese medicine composition according to claim 1 or 2 in preparing a medicament for treating depression, wherein the depression is caused by liver depression, spleen deficiency, incoordination between gallbladder and stomach, phlegm-dampness stagnation.
6. A medicament for treating depression caused by liver depression and spleen deficiency and excessive dampness, which is characterized by comprising the traditional Chinese medicine composition as claimed in claim 1 or 2 and pharmaceutically acceptable auxiliary materials or carriers.
7. The medicament according to claim 6, wherein the medicament is in the form of granules, tablets, decoction, capsules or syrups.
8. A traditional Chinese medicine granule for treating depression caused by liver depression and spleen deficiency and excessive dampness, which is characterized by comprising the traditional Chinese medicine composition as claimed in claim 1 or 2 and pharmaceutically acceptable auxiliary materials.
9. A method for preparing the traditional Chinese medicine granule according to claim 8, which is characterized by comprising the following steps:
weighing purified pinellia tuber, bupleurum, white paeony root, bamboo shavings, immature bitter orange, stir-fried bighead atractylodes rhizome, chinese angelica, moutan bark, gardenia, dried orange peel, tuckahoe, dragon bone, oyster, peppermint and honey-fried licorice root according to parts by weight for standby;
mixing the weighed medicinal materials, decocting in water, collecting decoction, concentrating at 50 ℃ and minus 0.06 to minus 0.08mpa, adding sugar powder and soluble starch into the obtained concentrate, granulating, drying, and finishing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211310613.6A CN115501305B (en) | 2022-10-25 | 2022-10-25 | Traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211310613.6A CN115501305B (en) | 2022-10-25 | 2022-10-25 | Traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115501305A CN115501305A (en) | 2022-12-23 |
| CN115501305B true CN115501305B (en) | 2023-11-21 |
Family
ID=84512853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211310613.6A Active CN115501305B (en) | 2022-10-25 | 2022-10-25 | Traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115501305B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116173173A (en) * | 2023-03-24 | 2023-05-30 | 河北医科大学第一医院 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
| CN116920052B (en) * | 2023-09-06 | 2024-04-19 | 南京市中医院 | Traditional Chinese medicine composition for treating primary sicca syndrome with depression and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102139086A (en) * | 2011-04-09 | 2011-08-03 | 河南中医学院 | Traditional Chinese medicine for treating liver constraint and spleen deficiency type post-stroke depression |
| CN103933487A (en) * | 2014-05-09 | 2014-07-23 | 厦门大学 | Compound traditional Chinese medicament for treating depression |
| CN106880776A (en) * | 2017-02-24 | 2017-06-23 | 威海康辉生物科技有限公司 | A kind of Chinese medicine composition for treating insomnia |
-
2022
- 2022-10-25 CN CN202211310613.6A patent/CN115501305B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102139086A (en) * | 2011-04-09 | 2011-08-03 | 河南中医学院 | Traditional Chinese medicine for treating liver constraint and spleen deficiency type post-stroke depression |
| CN103933487A (en) * | 2014-05-09 | 2014-07-23 | 厦门大学 | Compound traditional Chinese medicament for treating depression |
| CN106880776A (en) * | 2017-02-24 | 2017-06-23 | 威海康辉生物科技有限公司 | A kind of Chinese medicine composition for treating insomnia |
Non-Patent Citations (2)
| Title |
|---|
| 中西医结合治疗高血压病伴焦虑症状60例临床观察;孙春林;刘昌海;;新中医;-;第-卷(第01期);第60-61页 * |
| 丹栀逍遥散加味治疗卒中后抑郁的疗效观察;宋光明;杨娟;;天津中医药;-;第-卷(第04期);第296-298页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115501305A (en) | 2022-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115501305B (en) | Traditional Chinese medicine composition for treating depression caused by liver depression and spleen deficiency and excessive dampness and application thereof | |
| CN100425274C (en) | Insomnia treating Chinese medicine | |
| CN100493597C (en) | Medicine composition for treating neurosis | |
| CN101711847B (en) | Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis | |
| CN106214964A (en) | Traditional Chinese medicine for soothing nerves preparation | |
| CN103816519A (en) | Spleen-strengthening dampness-removing traditional Chinese medicine composition and preparation method thereof | |
| CN105327287A (en) | Pharmaceutical composition for treating psychosis and preparation technology thereof | |
| CN101810787B (en) | Chinese medicinal composition for treating dysphoria and preparation method thereof | |
| CN110123963A (en) | A kind of Chinese medicine sand table and its preparation method and application | |
| CN106421579B (en) | A kind of Chinese medicine composition and preparation method thereof for treating fatigue | |
| CN101607036A (en) | The application of a kind of Chinese medicine composition in the medicine of preparation treatment depression | |
| CN109646526B (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof | |
| CN106138668A (en) | A kind of Chinese medicine composition treating COPD and preparation method thereof | |
| CN104383421A (en) | Pharmaceutical preparation for treating insomnia and dreaminess | |
| CN104383420A (en) | Preparation method of pharmaceutical preparation for treating insomnia and dreaminess | |
| CN112316051B (en) | Traditional Chinese medicine composition for nourishing blood and reducing phlegm as well as traditional Chinese medicine preparation, preparation method and application thereof | |
| CN108143929B (en) | Medicine for treating vascular dementia | |
| CN102552677B (en) | Coptis chinensis and radix rehmanniae Anxiao capsule and preparation method thereof | |
| CN100998744A (en) | Chinese patent drug for treating infantile hyperkinetic syndrome | |
| CN104689151A (en) | Traditional Chinese medicine composition for treating diabetes and use of composition | |
| CN109876131A (en) | A kind of awake Chinese medicine of rush and preparation method thereof for treating craniocerebral injury stupor | |
| CN116920052B (en) | Traditional Chinese medicine composition for treating primary sicca syndrome with depression and preparation method and application thereof | |
| CN103736019B (en) | A kind of Chinese medicine preparation of Cure for insomnia dreaminess | |
| CN107837331A (en) | A kind of Chinese medicine composition for treating insomnia and preparation method thereof | |
| CN105434976B (en) | Anti-fatigue traditional Chinese medicine compound, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |